The M 1 muscarinic acetylcholine (mACh) receptor is among a growing number of G protein-coupled receptors that are able to activate multiple signaling cascades. AC-42 (4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl] piperidine) is an allosteric agonist that can selectively activate the M 1 mACh receptor in the absence of an orthosteric ligand. Allosteric agonists have the potential to stabilize unique receptor conformations, which may in turn cause differential activation of signal transduction pathways. In the present study, we have investigated the signaling pathways activated by AC-42, its analog 77-LH-28 subunits over basal; however, neither allosteric ligand produced a significant response. In contrast, both orthosteric and allosteric agonists are able to couple to the G␣ s /cAMP pathway, enhancing forskolin-stimulated cAMP accumulation. These data provide support for the concept that allosteric and orthosteric mACh receptor agonists both stabilize receptor conformations associated with G␣ q/11 -and G␣ s -dependent signaling; however, AC-42 and 77-LH-28-1, unlike oxo-M, arecoline, and pilocarpine, do not seem to promote M 1 mACh receptor-G␣ i1/2 coupling, suggesting that allosteric agonists have the potential to activate distinct subsets of downstream effectors.
]GTP␥S binding to G␣ i1/2 subunits over basal; however, neither allosteric ligand produced a significant response. In contrast, both orthosteric and allosteric agonists are able to couple to the G␣ s /cAMP pathway, enhancing forskolin-stimulated cAMP accumulation. These data provide support for the concept that allosteric and orthosteric mACh receptor agonists both stabilize receptor conformations associated with G␣ q/11 -and G␣ s -dependent signaling; however, AC-42 and 77-LH-28-1, unlike oxo-M, arecoline, and pilocarpine, do not seem to promote M 1 mACh receptor-G␣ i1/2 coupling, suggesting that allosteric agonists have the potential to activate distinct subsets of downstream effectors.
Muscarinic acetylcholine (mACh) receptors are family A members of the G protein-coupled receptor (GPCR) superfamily and are responsible for mediating the metabotropic effects of the neurotransmitter acetylcholine. In humans and other mammals, five subtypes of mACh receptor have been identified, termed M 1 to M 5 (Bonner et al., 1987) , and these have been further subdivided into M 1 /M 3 /M 5 and M 2 /M 4 subgroupings based on sequence similarities and their respective G q/11 and G i/o signal transduction coupling preferences (Caulfield and Birdsall, 1998) . Pharmacological manipulation of mACh receptor activity has the potential for positive therapeutic intervention in a variety of psychiatric and neurological diseases, including schizophrenia and Alzheimer's disease. It is unfortunate that despite much effort, relatively few truly subtype-selective mACh receptor agonists/antagonists have been reported. This lack of success has been attributed to the high level of sequence conservation among the amino acid residues within transmembrane domains III, V, VI, and VII, which form the orthosteric binding pocket of M 1 to M 5 mACh receptors (Hulme et al., 2003) . However, mACh receptors also possess allosteric binding sites distinct from the orthosteric binding site. Residues at the extracellular interface with transmembrane domain VII and within the second and third extracellular loops have been shown to be important for binding allosteric ligands (see Birdsall and Lazareno, 2005; Gregory et al., 2007) . These loci within the receptor are less well conserved than critical regions within the transmembrane core and represent sites within the receptor that could be exploited to develop subtype-specific ligands (Hulme et al., 2003; Gregory et al., 2007) . Spalding et al. (2002) have reported that a novel compound, AC-42, is able to activate selectively the M 1 mACh receptor. By constructing chimeric receptors, this group was able to demonstrate that AC-42 binds to a site (proposed to consist of residues in the N terminus and transmembrane 1 along with residues in transmembrane 7 and the third extracellular loop) distinct from the orthosteric site (Spalding et al., 2002) . The suggested "ectopic" location of the binding site was further supported by the discovery that an Y381A point mutation in the acetylcholine binding site was sufficient to abolish receptor activation by an orthosteric agonist but had no effect on the functional response to AC-42 (Spalding et al., 2002) . Subsequent work has demonstrated that AC-42 acts allosterically (Langmead et al., 2006) ; consequently, we use the term "allosteric agonist" here to describe AC-42.
Although it is well recognized that ligand binding to M 1 mACh receptors initiates G q/11 -dependent activation of phospholipase C and consequent generation of inositol 1,4,5-trisphosphate and 1,2-diacylglycerol, the ability of this receptor subtype to influence additional downstream effector pathways (via distinct G protein subtypes) has also been reported. Thus, the M 1 mACh receptor has been reported to activate G i/o and G q/11 proteins (Offermanns et al., 1994; Akam et al., 2001) and to activate adenylyl cyclase activity via a G s protein-dependent mechanism (Burford and Nahorski, 1996) . The ability of the M 1 mACh receptor to activate multiple downstream effectors via distinct signaling pathways allows the possibility that allosteric agonists like AC-42 may not only display functional mACh receptor subtype selectivity but also may activate all or a subset of the pathways activated by orthosteric agonists. This phenomenon, referred to variously as "agonist-directed trafficking of receptor stimulus," "functional selectivity," and most recently as "ligandinduced differential signaling" (Kenakin, 2003; Urban et al., 2007) , has been reported for a number of receptors including pituitary adenylyl cyclase-activating protein receptors (Spengler et al., 1993) , 5-hydroxytryptamine 2C receptors (Berg et al., 1998) , and CB 1 cannabinoid receptors (Bonhaus et al., 1998) . Previous work exploring G i/o coupling through the M 1 and M 3 mACh receptors revealed differences between methacholine-and pilocarpine-stimulated [
35 S]GTP␥S binding to G i/o proteins (Akam et al., 2001) , and this orthosteric agonistspecific activation was also observed at M 2 and M 4 mACh receptors, where pilocarpine seems to selectively activate G i3 over G i1 and/or G i2 proteins (Akam et al., 2001) .
AC-42 has been shown to stimulate both phosphoinositide hydrolysis and a Ca 2ϩ response consistent with activation of G␣ q/11 subunits (Spalding et al., 2002 (Spalding et al., , 2006 Langmead et al., 2006 Langmead et al., , 2008 . However, investigation of alternative signaling pathways activated by allosteric agonists at the M 1 mACh receptor remains largely uncharacterized. Therefore, in this study, we have investigated the actions of AC-42, its analog 77-LH-28-1 (Langmead et al., 2008) , and orthosteric mACh receptor agonists [oxotremorine-M (oxo-M), arecoline, and pilocarpine] to determine whether these compounds differentially affect receptor-G protein coupling, assessing these effects at the level of receptor recognition, G protein coupling, and signal transduction pathway activation. 3 H]inositol, and protein A-Sepharose CL-4B were from GE Healthcare (Chalfont St. Giles, UK). Charcoal and borosilicate coverslips were from BDH (Poole, Dorset, UK). Primary antibody for G␣ q/11 was generated against the common 11-mer C terminus sequence LQLNLKEYNLV as described previously (Akam et al., 2001 ). Primary antibody for G␣ i was generated by Cambridge Research Biochemicals (Northwich, UK) against the common G␣ i1/2 C-terminal 10-mer sequence KENLKDCGLF. AC-42 and 77-LH-28-1 were synthesized "in-house" by GlaxoSmithKline (Harlow, UK).
Materials and Methods

Materials
Cell Culture. Chinese hamster ovary cells stably expressing the recombinant human M 1 mACh receptor (CHO-M 1 cells), originally obtained from Dr. Noel Buckley (then at National Institutes for Medical Research, London, UK), were grown in minimal essential medium-␣ supplemented with fetal bovine serum (10%), penicillin (50 units/ml), streptomycin (50 g/ml), and amphotericin B (2.5 g/ml). Cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 in air.
Cell Membrane Preparation. Confluent monolayers of CHO-M 1 cells were rapidly washed with 10 mM HEPES, 0.9% NaCl, and 0.2% EDTA, pH 7.4 (HBS-EDTA) before incubation with HBS-EDTA for 15 min to lift cells. Cells were centrifuged (400g, 4 min), and the pellet was resuspended in 10 mM HEPES and 10 mM EDTA, pH 7.4, homogenized using a Polytron homogenizer (3 ϫ 5-s bursts; Kinematica AG, Littau, Switzerland) and centrifuged (40,000g, 15 min, 4°C). The cell pellet was resuspended in 10 mM HEPES and 0.1 mM EDTA, pH 7.4, and rehomogenized and centrifuged as described above. The final pellet was resuspended in the 10 mM HEPES and 10 mM EDTA, pH 7.4, buffer to give a final protein concentration of 2 mg/ml and either used immediately or snap-frozen and stored at Ϫ80°C.
[ 3 H]NMS Binding.
[ 3 H]NMS inhibition binding assays were carried out as described previously (Mistry et al., 2005) . In general, CHO-M 1 cells were seeded at a density of 75,000 cells/well in 24-well plates. The next day, cells were washed three times with warmed KHB (composition: 118 mM NaCl, 8.5 mM HEPES, 4.7 mM KCl, 4 mM NaHCO 3 , 1.3 mM CaCl 2 , 1.2 mM MgSO 4 .7H 2 O, 1.2 mM KH 2 PO 4 , and 11.7 mM glucose, pH 7.4) before being maintained on ice in a total assay volume of 1 ml of ice-cold KHB containing appropriate concentrations of agonists and approximately 0.2 nM [ 3 H]NMS. After a 5-h incubation at 4°C cells were washed three times with ice-cold KHB before the addition of 0.1 M NaOH (500 l). After cell solubilization, SafeFluor scintillation fluid was added, and samples were counted.
[ 35 S]GTP␥S Binding and Immunoprecipitation of G␣ Subunits. [ 35 S]GTP␥S binding and immunoprecipitation of G␣ subunits was performed as described previously (Akam et al., 2001) . In general, CHO-M 1 membranes were diluted in assay buffer (10 mM HEPES, 100 mM NaCl, and 10 mM MgCl 2 , pH 7.4) to give a final protein concentration of 75 g per 50 l. Membranes were then added to assay buffer containing final concentrations of 1 nM [ 35 S]GTP␥S and either 1 or 10 M GDP (see Results). Membranes were incubated at 30°C for 2 or 5 min (see Results) with agonists before reactions were terminated by the addition of 1 ml of ice-cold assay buffer and immediate transfer to an ice bath. Samples were centrifuged (20,000g, 6 min, 4°C), and membrane pellets were solubilized by the addition of 50 l of ice-cold solubilization buffer (100 mM Tris/HCl, 200 mM NaCl, 1 mM EDTA, 1.25% Igepal, and 0.2% SDS, pH 7.4) and regular vortex mixing over 30 min. After complete protein resolubilization, 50 l of solubilization buffer without SDS jpet.aspetjournals.org was added. Solubilized protein was precleared using normal rabbit serum at a dilution of 1:100 and 3% (w/v) protein A-Sepharose beads in TE buffer (10 mM Tris/HCl and 10 mM EDTA, pH 8.0) added for 60 min at 4°C. Protein A-Sepharose beads and insoluble material were collected by centrifugation (20,000g, 6 min, 4°C), and 100 l of the supernatant was transferred to fresh tubes containing G proteinspecific anti-serum. Samples were vortex-mixed and rotated at 4°C for 90 min before being centrifuged (20,000g, 6 min, 4°C). Supernatants were aspirated, and the protein A-Sepharose beads were washed three times with ice-cold solubilization buffer (without SDS). Recovered beads were then mixed with 1 ml of FloScint-IV scintillation cocktail and counted by liquid scintillation spectrometry.
cAMP Accumulation Assay. CHO-M 1 cells seeded at 100,000 cells/well in 24-well plates 2 days before assay were washed twice before the addition of 450 l of Ca 2ϩ -free KHB containing 100 M EGTA. Cells were incubated at 37°C with agonists for 10 min before termination by aspiration of buffer and addition of ice-cold 0.5 M trichloroacetic acid (400 l). After addition of 50 l of 10 mM EDTA, samples were mixed with 500 l of 1,1,2-trichlorofluoroethane:tri-noctylamine (1:1, v/v). Samples were centrifuged at 16,000g for 4 min, and 200 l of the upper phase was removed. Sample pH was brought to approximately 7.5 by the addition of 50 l of 60 mM NaHCO 3 . cAMP concentrations were determined using a binding assay as described previously (Mistry et al., 2005) .
Total [ 3 H]Inositol Phosphate Accumulation Assay. CHO-M 1 cells were seeded at 100,000 cells/well in 24-well plates and incubated in fresh medium containing 2.5 Ci/ml [ 3 H]inositol for 48 h. Confluent cell monolayers were washed twice in KHB, and then 275 l of KHB containing 10 mM LiCl was added. Cells were incubated for 30 min at 37°C before the addition of agonist or vehicle for 15 min. Reactions were terminated by the addition of ice-cold trichloroacetic acid (1 M), and samples were neutralized using the freon/tri-noctylamine method as described above. The [ 3 H]inositol mono-, bis-, and trisphosphate ([ 3 H]InsP x ) fraction was recovered by anion exchange chromatography. Dowex-1 (formate form) columns were regenerated with 10 ml of ammonium formate (2 M)/formic acid (0.1 M) before being washed extensively with distilled water. Samples were washed onto the columns with 5 ml of distilled water. Columns were initially washed with 10 ml of ammonium formate (60 mM)/sodium tetraborate (5 mM). The [ 3 H]InsP x fraction was then eluted in 10 ml of ammonium formate (0.75 M)/formic acid (0.1 M). A 5-ml aliquot of the collected eluate was mixed with 10 ml of SafeFluor scintillation cocktail, and radioactivity was determined by liquid scintillation counting.
Ins(1,4,5)P 3 Mass Assay. CHO-M 1 cells seeded at 100,000 cells/ well in 24-well plates 2 days before assay were washed twice, and 450 l of warmed KHB was added for 30 min at 37°C before the addition of maximal agonist concentrations for the times indicated. Reactions were terminated by the addition of ice-cold trichloroacetic acid (0.5 M) and extracted using the freon/tri-n-octylamine method as described above. Determination of Ins(1,4,5)P 3 concentrations was by a competition binding assay described previously (Challiss et al., 1988) .
Single-Cell Imaging of Ins(1,4,5)P 3 . CHO-M 1 cells were seeded onto 25-mm glass coverslips and transiently transfected with the enhanced green fluorescent protein tagged to the pleckstrin homology domain of phospholipase C␦ (eGFP-PH) construct (Stauffer et al., 1998) using Lipofectamine2000 according to the manufacturer's instructions. After 48 h, translocation of the eGFP-PH biosensor was visualized using an Olympus FV500 confocal microscope (Olympus, Tokyo, Japan), with cells maintained at 37°C and perfused with KHB (5 ml/min). Changes in the cell localization of eGFP-PH were expressed as a change in cytosolic fluorescence relative to basal as described previously (Nash et al., 2002) . Drugs were applied through a perfusion line for the times indicated.
Data Analysis. All data are expressed as mean Ϯ S.E.M. for the indicated number of experiments or as a representative trace of at least three independent experiments. Radioligand binding data and agonist concentration-response curves were analyzed using Prism 4.0 (GraphPad Software Inc., San Diego, CA). IC 50 values derived from agonist displacement of [ 3 H]NMS binding were converted to K b values using the method of Cheng and Prusoff (1973) . For calculation of the initial rate of Ins(1,4,5)P 3 accumulation in eGFP-PH fluorescent imaging experiments, basal and peak fluorescence values were defined within an area of interest in the cytoplasm (see Bartlett et al., 2005) ; the time taken for the fluorescence to increase from 10 to 90% of the (peak Ϫ basal) value was determined, as was the magnitude of the 10 3 90% fluorescence change; this allowed the calculation of an initial rate as arbitrary fluorescence units (AFU) per second. Statistical differences between multiple data sets were assessed by one-way analysis of variance followed by Bonferroni's multiple-range test at P Ͻ 0.05 using Prism 4.0 (GraphPad Software Inc.). For agonist potency ranking, Ͼ represents a statistically significant difference, and Ϸ represents no difference.
Results
Both AC-42 and 77-LH-28-1, a structural homolog, have been reported previously to have an allosteric mechanism of action (Langmead et al., 2006; Spalding et al., 2006; May et al., 2007 3 H]NMS in the presence of varying agonist concentrations at 4°C for 5 h (to achieve equilibrium binding without causing receptor internalization). The apparent binding affinity (pK B ) and Hill slope for each agonist are summarized in Table 1 . 77-LH-28-1 displayed a significantly higher binding affinity than AC-42, oxo-M, arecoline, and pilocarpine (P Ͻ 0.05).
Analysis of M 1 mACh Receptor-G␣ q/11 Coupling. Agonist stimulation in the presence of [
35 S]GTP␥S and subsequent immunoprecipitation of specific G␣-subunits allows examination of a proximal signaling event in membrane preparations from a number of cells/tissues (Friedman et al., 1993; Lazareno and Birdsall, 1993; Akam et al., 2001 ). This technique has been optimized in a CHO cell background to show that the concentration-dependent increase in [ 35 S]-GTP␥S-G␣ q/11 binding, stimulated by the human M 1 mACh receptor, is optimal in the presence of 1 M GDP after 2-min incubations at 30°C (Akam et al., 2001 Fig. 1; Table 2 ). The M 1 -selective allosteric agonists, AC-42 and 77-LH-28-1, were partial agonists with respect to oxo-M, eliciting approximately 30 and 60% of the oxo-M response, respectively (Fig.  1A) . 77-LH-28-1 was more potent than AC-42, causing an increase in [
35 S]GTP␥S-G␣ q/11 binding with an EC 50 value of approximately 0.4 compared with 1.6 M for AC-42 (Table 2) . Pilocarpine and arecoline also behaved as partial agonists with respect to oxo-M, causing approximately 35 and 60% of the maximal response (Fig. 1B) . Thus, AC-42 displays comparable relative efficacy to the orthosteric agonist pilocarpine in activating G␣ q/11 subunits, whereas 77-LH-28-1 is comparable with the orthosteric agonist arecoline. Time courses for agonist-stimulated increases in G␣ q/11 -[
35 S]GTP␥S binding are shown as insets to Fig. 1, A Table 2 ). accumulation assay provides an index of PLC activity, we also conducted experiments to investigate the time course of Ins(1,4,5)P 3 accumulation in CHO-M 1 cells to compare further the activation profiles of allosteric and orthosteric agonists with respect to G␣ q/11 -coupled downstream signaling. Basal levels of Ins(1,4,5)P 3 were 44 Ϯ 3 pmol/mg protein (n ϭ 12) in cell population experiments. oxo-M (100 M) caused a biphasic rise in Ins(1,4,5)P 3 levels, with an initial peak of 703 Ϯ 37 pmol/mg protein after 15 s, falling to a plateau level (278 Ϯ 20 pmol/mg protein) sustained from 60 s onwards (Fig. 3) . In contrast, activation of CHO-M 1 cells by either arecoline (1 mM) or pilocarpine (1 mM) caused monophasic Ins(1,4,5)P 3 accumulation profiles, with maxima being reached at around 60 s (Fig.  3B) . It was notable that the "steady-state" Ins(1,4,5)P 3 accumulations caused by oxo-M, arecoline, and pilocarpine between 60 and 300 s were similar (approximately 300 pmol/mg protein). The allosteric agonist 77-LH-28-1 (10 M) caused a similar monophasic profile of Ins(1,4,5)P 3 accumulation to the orthosteric partial agonists, achieving a similar steady-state value (Fig. 3A) . In contrast, stimulation with AC-42 (100 M) produced a modest, monophasic increase in Ins(1,4,5)P 3 accumulation (reaching 122 Ϯ 9 pmol/mg protein at 120 s; Fig. 3A) , which was significantly lower than steady-state values for all of the other agonists examined (P Ͻ 0.01).
Complementary experiments were performed using the fluorescent biosensor eGFP-PH to visualize real-time changes in Ins(1,4,5)P 3 levels in single CHO-M 1 cells. At rest, eGFP-PH is maintained at the plasma membrane because of its affinity for phosphatidylinositol 4,5-bisphosphate. On PLC activation, the biosensor translocates to the cytoplasm because of its greater affinity for Ins(1,4,5)P 3 . Therefore, increases in cytoplasmic fluorescence provide an index of the changes in Ins(1,4,5)P 3 (and/or phosphatidylinositol 4,5-bisphosphate) levels and, hence, PLC activity. This experimental technique was used specifically to assess the relative rates of activation of phosphoinositide turnover caused by the different orthosteric and allosteric agonists (Fig. 4) . Stimulation with oxo-M (100 M, 30 s) induced a rapid increase in Ins(1,4,5)P 3 accumulation, which peaked at 15 to 30 s and immediately declined toward baseline on agonist washout (Fig. 4A) . Consistent with the cell population time courses, arecoline (1 mM), pilocarpine (1 mM), and 77-LH-28-1 (10 M) caused smaller peak Ins(1,4,5)P 3 accumulations. To analyze the initial rates of second messenger generation, basal and peak fluorescence levels were defined, and the Table 2 ).
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at ASPET Journals on August 30, 2017 jpet.aspetjournals.org change between 10 and 90% of peak Ins(1,4,5)P 3 accumulation was determined and expressed as a change in cytoplasmic fluorescence [which is directly proportional to Ins(1,4,5)P 3 accumulation] per unit time (see Materials and Methods). Using this index of the rate of increase in Ins(1,4,5)P 3 (expressed as arbitrary fluorescence units per second), we found that oxo-M caused the most rapid response (23.6 Ϯ 8.4 AFU/s), with arecoline (8.2 Ϯ 3.3 AFU/s), pilocarpine (8.0 Ϯ 1.0 AFU/s), and 77-LH-28-1 (7.1 Ϯ 3.8 AFU/s) giving essentially similar, but slower, rates. In comparison with oxo-M, Ins(1,4,5)P 3 accumulations stimulated by arecoline, pilocarpine, and 77-LH-28-1 declined quite slowly over a 300-to 500-s period (Fig. 4, A and  B) . Cell-to-cell variation in responses to AC-42 (100 M) was greater than for the other agonists studied, and in some cells (see Fig. 4B ), AC-42 was able to cause a peak Ins(1,4,5)P 3 accumulation comparable with the other partial agonists (Fig.  4B) ; however, the rate of rise evoked by AC-42 was always much slower than for the other agonists (1.5 Ϯ 0.5 AFU/s).
Analysis of Receptor-G␣ i1/2 Coupling. Although the M 2 and M 4 mACh receptor subtypes couple preferentially to G i/o proteins (Caulfield and Birdsall, 1998) , it has been demonstrated that the M 1 and M 3 mACh receptor subtypes are also capable of activating G␣ i subunits in addition to G␣ q/11 subunits (Offermanns et al., 1994; Akam et al., 2001) . To investigate whether the M 1 mACh receptor-selective allosteric agonists can cause the M 1 mACh receptor to activate multiple G protein-dependent pathways, we first assessed the agonist-dependent activation of G␣ i subunits in CHO-M 1 membranes.
In initial experiments designed to optimize the [ 35 S]GTP␥S-G␣ q/11 binding curve (see Fig. 5B ; Table 2 ). Arecoline and pilocarpine both stimulated significant increases in [
35 S]GTP␥S-G␣ i1/2 binding over basal (Fig. 5, A and B) , with their respective concentration-response curves also lying approximately 10-fold to the right of their respective [
35 S]GTP␥S-G␣ q/11 binding responses (Table 2 ). In contrast, neither allosteric agonist [at concentrations up to 30 M (77-LH-28-1) or 300 M (AC-42)] was able to cause a significant increase in [
35 S]GTP␥S-G␣ i1/2 binding in CHO-M 1 membranes ( Fig. 5A; Table 2 ). These data suggest that the allosteric agonists are less able to facilitate M 1 mACh receptor-dependent GTP/GDP exchange on G␣ i1/2 proteins compared with orthosteric partial agonists that are equiefficacious with respect to other signaling readouts.
Analysis of Receptor-G␣ s Coupling. To explore the potential coupling of the M 1 mACh receptor to G␣ s in the CHO cell background (Burford and Nahorski, 1996) Carruthers et al., 1999) . Under these conditions, none of the mACh receptor agonists caused a detectable increase in [
35 S]-GTP␥S-G␣ s binding.
As an alternate index of mACh receptor-G␣ s activation, we measured cAMP accumulation in intact CHO-M 1 cells. Addition of oxo-M (100 M) caused a robust 10-to 20-fold increase in cAMP accumulation (basal, 11 Ϯ 3; ϩoxo-M, 183 Ϯ 8 pmol/mg protein; pEC 50 , 5.05 Ϯ 0.08); however, none of the partial agonists caused a significant increase over basal (data not shown). In contrast, arecoline, pilocarpine, AC-42, and 77-LH-28-1 significantly enhanced the increase in cAMP accumulation caused by forskolin (1 M). Previous studies have found that under these conditions, receptor activation in CHO cells can indirectly modulate forskolin-stimulated adenylyl cyclase activity through activation of Ca 2ϩ entry and Ca 2ϩ -dependent effects on isoforms of adenylyl cyclase (Cooper et al., 1995) . Therefore, in these assays, Ca 2ϩ was omitted from the medium, and EGTA (100 M) was added to remove the possibility of Ca 2ϩ entry-driven effects on M 1 mACh receptor-mediated cAMP responses. Under these conditions, all agonists induced concentration-dependent, monophasic enhancements of forskolin-stimulated cAMP accumulation (Fig. 6) . oxo-M caused a 7.5-fold enhancement of the forskolin-stimulated response (ϩforskolin, 151 Ϯ 10; ϩforskolin/oxo-M, 1130 Ϯ 66 pmol/mg protein). Arecoline, pilocarpine, AC-42, and 77-LH-28-1 all behaved as partial agonists with respect to the maximal oxo-M response (Fig. 6 , A and B; Table 2 ). The rank order of potency with respect to cAMP accumulation was 77-LH-28-1 (6.01) Ϸ oxo-M (5.71) Ͼ AC-42 (5.06) Ϸ arecoline (4.61) Ϸ pilocarpine (4.41).
Discussion
The present study provides a profile of the proximal signaling pathways coupled to an allosteric agonist of the M 1 mACh receptor, AC-42 (Spalding et al., 2002) , and a closely related compound, 77-LH-28-1 (May et al., 2007; Langmead et al., 2008) . In general, we have focused on the ability of orthosteric and allosteric mACh receptor agonists to activate G␣ q/11 -dependent signaling events and explored the ability of these agonists to stimulate M 1 mACh receptor coupling to alternative G i/o and G s protein-dependent signaling pathways. Although orthosteric and allosteric agonists share many properties, we have demonstrated that there exist subtle differences in the signaling outcomes these two subclasses of agonist are able to activate.
Initial assessment of the abilities of orthosteric and allosteric agonists to promote M 1 mACh receptor-G␣ q/11 protein coupling in the CHO-M 1 membranes used the [ 35 S]GTP␥S binding assay (Hilf et al., 1989; Lazareno and Birdsall, 1993) adapted to distinguish [
35 S]GTP␥S binding to specific G␣ protein subpopulations (Friedman et al., 1993; Akam et al., 2001) . Consistent with previous work (Spalding et al., 2002 (Spalding et al., , 2006 Langmead et al., 2006 Langmead et al., , 2008 (Table 2) .
To gain a more kinetic perspective on the actions of the different mACh receptor agonists on PLC activity, temporal profiles for Ins(1,4,5)P 3 accumulation were also investigated. Ins(1,4,5)P 3 response profiles vary both with respect to the initiating GPCR and the pharmacological properties of the stimulating agonist (Willars and Nahorski, 1995; Nash et al., 2002; Bartlett et al., 2005) . Here, only the full agonist oxo-M stimulated a rapid, peak-and-plateau Ins(1,4,5)P 3 response. Monophasic increases in Ins(1,4,5)P 3 , reaching similar plateau levels to those seen for oxo-M after 60 to 120 s, were seen for arecoline, pilocarpine, and 77-LH-28-1. In contrast, AC-42, which yielded similar pEC 50 and R max values to pilocarpine with respect to stimulating [ 35 S]GTP␥S-G␣ q/11 binding (see Table 2 ), stimulated a monophasic increase in Ins-(1,4,5)P 3 that was Ͻ50% of that achieved by the other partial agonists. Further differences between the agonists used were illustrated by single-cell studies of Ins(1,4,5)P 3 generation, using eGFP-PH (Stauffer et al., 1998; Nash et al., 2002) . Application of oxo-M caused a rapid increase in eGFP-PH translocation from the plasma membrane to the cytoplasm, which rapidly reversed on agonist washout. Arecoline, pilocarpine, and 77-LH-28-1 gave broadly similar responses to each other, with slower increases, lower maxima, and slower reversibility on washout than oxo-M. Greater variation in individual responses was seen with respect to eGFP-PH translocation after AC-42 application (delivered either by perfusion or direct bath application). Although the eventual extent of eGFP-PH translocation caused by AC-42 in some cells approached that caused by 77-LH-28-1, the rate of rise was always slow (Ͼ10-fold slower relative to oxo-M). These data clearly indicate kinetic differences between the ago- 35 S]GTP␥S binding to G␣ i1/2 subunits in CHO-M 1 cell membranes. CHO-M 1 cell membranes were incubated with oxo-M (100 M; n ϭ 7), arecoline (1 mM; n ϭ 5), pilocarpine (1 mM; n ϭ 7), AC-42 (100 M; n ϭ 8), or 77-LH-28-1 (30 M; n ϭ 7) in the presence of 10 M GDP and 1 nM [ 35 S]GTP␥S for 2 min at 30°C (A). Incubations were terminated after this time, and specific G␣ subunits were immunoprecipitated as described under Materials and Methods. Statistically significant differences are indicated as follows: ‫,ء‬ P Ͻ 0.05; and ‫,ءء‬ P Ͻ 0.01. A, inset, time course of change in [
35 S]GTP␥S-G␣ i1/2 binding in the absence and presence of oxo-M (10 M). Concentration-dependent increases in [
35 S]GTP␥S-G␣ i1/2 binding stimulated by oxo-M (n ϭ 5), arecoline (n ϭ 4), or pilocarpine (n ϭ 6) are shown in B. All data are presented as means Ϯ S.E.M. for the indicated number of separate experiments (see Table 2 ) performed in duplicate. Fig. 6 . Concentration-dependent effects of mACh receptor agonists on forskolin-stimulated cAMP accumulation. Confluent CHO-M 1 cell monolayers were washed twice in Ca 2ϩ -free KHB before incubation in the presence of the indicated concentrations of mACh receptor agonists for 10 min before the addition of forskolin (1 M) for 10 min. After this time, incubations were terminated, and cAMP levels were determined as described under Materials and Methods. Data are shown for AC-42 and 77-LH-28-1 (A) and arecoline and pilocarpine (B); oxo-M data are reproduced in both panels. Data are presented as means Ϯ S.E.M. for the indicated number of separate experiments (see Table 2 ) performed in duplicate.
